The immunomodulatory effect of sugammadex in vitro and after total hip arthroplasty : A randomised controlled pilot and retrospective cohort study
Main findingResult — go to the resultOdds ratio 1.000 95% CI 0.998–1.002Authors' conclusion
Sugammadex preserved cytokine production capacity of TNF and IL-1β in vitro . The clinical pilot study and retrospective cohort study revealed no early postoperative immunomodulatory effects for sugammadex in the clinically used dosing range.
Study context
- Population
- Healthy donors (in vitro), adults undergoing total hip arthroplasty under single shot spinal anaesthesia (pilot), major abdominal surgery patients (cohort); tertiary teaching hospital12 donors, 20 THA, 1000 cohort
- Comparison
- Sugammadex vs placebo; sugammadex and rocuronium exposure in vitro
- Outcome
- In vitro: TNF, IL-1β and IL-6 production capacity; pilot: ex-vivo cytokine production capacity after whole blood lipopolysaccharides (LPS) stimulation; cohort: sugammadex as predictor of postoperative infectious complications
Methodological detailsin-vitro experiment, randomised controlled pilot study, retrospective cohort study
- In-vitro experiment
- Randomised controlled pilot study
- Retrospective cohort study
Main finding
As reported in the abstract
Odds ratio
1.000
95% CI 0.998–1.002
Sugammadex vs Placebo
OR 1.000 (95% CI 0.998–1.002)
Original publication
The immunomodulatory effect of sugammadex in vitro and after total hip arthroplasty : A randomised controlled pilot and retrospective cohort study. Eur J Anaesthesiol. Published 14 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →